Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radotinib in early Parkinson's disease
2024-516549-37-00Phase 2Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Radotinib with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Apr 2021; status: completed.
02
Drugs
radotinib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2024-516549-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516549-37-00.